These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25407358)

  • 1. The cost-effectiveness of sacral nerve stimulation (SNS) for the treatment of idiopathic medically refractory overactive bladder (wet) in the UK.
    Autiero SW; Hallas N; Betts CD; Ockrim JL
    BJU Int; 2015 Dec; 116(6):945-54. PubMed ID: 25407358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder.
    Arlandis S; Castro D; Errando C; Fernández E; Jiménez M; González P; Crespo C; Staeuble F; Rodríguez JM; Brosa M
    Value Health; 2011; 14(2):219-28. PubMed ID: 21402292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin?
    Tubaro A; Puccini F; De Nunzio C
    Curr Opin Urol; 2015 Jul; 25(4):305-10. PubMed ID: 26049873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System.
    Bertapelle MP; Vottero M; Popolo GD; Mencarini M; Ostardo E; Spinelli M; Giannantoni A; D'Ausilio A
    World J Urol; 2015 Aug; 33(8):1109-17. PubMed ID: 25218855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder.
    Leong RK; de Wachter SG; Joore MA; van Kerrebroeck PE
    BJU Int; 2011 Aug; 108(4):558-64. PubMed ID: 21166750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation.
    Martinson M; MacDiarmid S; Black E
    J Urol; 2013 Jan; 189(1):210-6. PubMed ID: 23174264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United States.
    Kraus SR; Shiozawa A; Szabo SM; Qian C; Rogula B; Hairston J
    Neurourol Urodyn; 2020 Nov; 39(8):2206-2222. PubMed ID: 32827230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of overactive bladder treatments: from the US payer perspective.
    Murray B; Hessami SH; Gultyaev D; Lister J; Dmochowski R; Gillard KK; Stanisic S; Tung A; Boer R; Kaplan S
    J Comp Eff Res; 2019 Jan; 8(1):61-71. PubMed ID: 30511584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PNE versus 1st stage tined lead procedure: a direct comparison to select the most sensitive test method to identify patients suitable for sacral neuromodulation therapy.
    Leong RK; De Wachter SG; Nieman FH; de Bie RA; van Kerrebroeck PE
    Neurourol Urodyn; 2011 Sep; 30(7):1249-52. PubMed ID: 21404317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient preferences for treating refractory overactive bladder in the UK.
    Hashim H; Beusterien K; Bridges JF; Amos K; Cardozo L
    Int Urol Nephrol; 2015 Oct; 47(10):1619-27. PubMed ID: 26347077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis Between Sacral Neuromodulation and OnabotulinumtoxinA for the Treatment of Refractory Overactive Bladder in Women: A Systematic Review.
    Gerjevic KA; Ahmad S; Strohbehn K; Riblet N
    Female Pelvic Med Reconstr Surg; 2021 Aug; 27(8):481-487. PubMed ID: 34074937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of Sacral Nerve Stimulation for Treatment of Refractory Overactive Bladder Among Octogenarians.
    Greenberg DR; Syan R; Young-Lin N; Comiter CV; Enemchukwu E
    Neuromodulation; 2019 Aug; 22(6):738-744. PubMed ID: 31215713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of BTX-A and neuromodulation in treating OAB with or without detrusor overactivity: a systematic review.
    Rachaneni S; Latthe P
    Int Urogynecol J; 2017 Jun; 28(6):805-816. PubMed ID: 28083714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percutaneous tibial nerve stimulation: a clinically and cost effective addition to the overactive bladder algorithm of care.
    Staskin DR; Peters KM; MacDiarmid S; Shore N; de Groat WC
    Curr Urol Rep; 2012 Oct; 13(5):327-34. PubMed ID: 22893501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and adverse events of sacral nerve stimulation for overactive bladder: A systematic review.
    Siddiqui NY; Wu JM; Amundsen CL
    Neurourol Urodyn; 2010; 29 Suppl 1():S18-23. PubMed ID: 20419795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contemporary Patterns of Third-line Treatments for Privately Insured Individuals With Overactive Bladder in the United States.
    Jiang J; Patil D; Traore EJ; Hammett J; Filson CP
    Urology; 2020 Aug; 142():87-93. PubMed ID: 32437771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder.
    Chen HW; Bercik RS; Werner EF; Thung SF
    J Urol; 2012 Jan; 187(1):178-84. PubMed ID: 22100006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost Effectiveness of Sacral Neuromodulation and OnabotulinumtoxinA in Managing Refractory Idiopathic Overactive Bladder.
    Tay LJ; Harry D; Malde S; Sahai A
    Urology; 2021 Mar; 149():1-10. PubMed ID: 33227305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
    Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
    J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sacral nerve stimulation reduces elevated urinary nerve growth factor levels in women with symptomatic detrusor overactivity.
    Shalom DF; Pillalamarri N; Xue X; Kohn N; Lind LR; Winkler HA; Metz CN
    Am J Obstet Gynecol; 2014 Nov; 211(5):561.e1-5. PubMed ID: 25019486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.